Status:
COMPLETED
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Lead Sponsor:
Astellas Pharma a/s
Conditions:
Metastatic Castration Resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary purpose is to evaluate overall ...
Detailed Description
The data source in this study is a local hospital registry created from a patient follow up of prostate cancer patients.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Chemo naïve mCRPC patients treated with enzalutamide and ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration).
- mCRPC patients treated with enzalutamide and ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration) post chemo.
- Exclusion Criteria
- mCRPC patients previously exposed to Radium-223, abiraterone acetate and/or cabazitaxel for mCRPC (pre- and post chemotherapy).
- Patients previously exposed to chemotherapy or abiraterone acetate+prednisolone in combination with GnRH analogue for hormone sensitive prostate cancer (HSPC).
Exclusion
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 24 2017
Estimated Enrollment :
211 Patients enrolled
Trial Details
Trial ID
NCT03328364
Start Date
December 1 2017
End Date
December 24 2017
Last Update
November 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site SE46001
Malmo, Sweden